These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 24025560

  • 1. BPR0C305, an orally active microtubule-disrupting anticancer agent.
    Li WT, Yeh TK, Song JS, Yang YN, Chen TW, Lin CH, Chen CP, Shen CC, Hsieh CC, Lin HL, Chao YS, Chen CT.
    Anticancer Drugs; 2013 Nov; 24(10):1047-57. PubMed ID: 24025560
    [Abstract] [Full Text] [Related]

  • 2. BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities.
    Hu CB, Chen CP, Yeh TK, Song JS, Chang CY, Chuu JJ, Tung FF, Ho PY, Chen TW, Lin CH, Wang MH, Chang KY, Huang CL, Lin HL, Li WT, Hwang DR, Chern JH, Hwang LL, Chang JY, Chao YS, Chen CT.
    Cancer Sci; 2011 Jan; 102(1):182-91. PubMed ID: 21040217
    [Abstract] [Full Text] [Related]

  • 3. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP, Hsu KS, Kuo CC, Chang CY, Chang JY.
    J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and biological activities of 2-amino-1-arylidenamino imidazoles as orally active anticancer agents.
    Li WT, Hwang DR, Song JS, Chen CP, Chuu JJ, Hu CB, Lin HL, Huang CL, Huang CY, Tseng HY, Lin CC, Chen TW, Lin CH, Wang HS, Shen CC, Chang CM, Chao YS, Chen CT.
    J Med Chem; 2010 Mar 25; 53(6):2409-17. PubMed ID: 20170097
    [Abstract] [Full Text] [Related]

  • 5. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [Abstract] [Full Text] [Related]

  • 6. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY.
    Cancer Res; 2004 Jul 01; 64(13):4621-8. PubMed ID: 15231674
    [Abstract] [Full Text] [Related]

  • 7. An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
    Colley HE, Muthana M, Danson SJ, Jackson LV, Brett ML, Harrison J, Coole SF, Mason DP, Jennings LR, Wong M, Tulasi V, Norman D, Lockey PM, Williams L, Dossetter AG, Griffen EJ, Thompson MJ.
    J Med Chem; 2015 Dec 10; 58(23):9309-33. PubMed ID: 26580420
    [Abstract] [Full Text] [Related]

  • 8. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB, Ko BC.
    Clin Cancer Res; 2005 Aug 15; 11(16):6002-11. PubMed ID: 16115945
    [Abstract] [Full Text] [Related]

  • 9. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S, Hwang DJ, Barrett CM, Yang J, Duke CB, Miller DD, Dalton JT.
    Cancer Chemother Pharmacol; 2011 Feb 15; 67(2):293-304. PubMed ID: 20383708
    [Abstract] [Full Text] [Related]

  • 10. Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities.
    Liu Z, Zhou Z, Tian W, Fan X, Xue D, Yu L, Yu Q, Long YQ.
    ChemMedChem; 2012 Apr 15; 7(4):680-93. PubMed ID: 22311585
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
    Jiang JD, Denner L, Ling YH, Li JN, Davis A, Wang Y, Li Y, Roboz J, Wang LG, Perez-Soler R, Marcelli M, Bekesi G, Holland JF.
    Cancer Res; 2002 Nov 01; 62(21):6080-8. PubMed ID: 12414632
    [Abstract] [Full Text] [Related]

  • 13. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
    Cai D, Qiu Z, Yao W, Liu Y, Huang H, Liao S, Luo Q, Xie L, Lin Z.
    Cancer Chemother Pharmacol; 2016 Jun 01; 77(6):1217-29. PubMed ID: 27107592
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA.
    Clin Cancer Res; 2001 May 01; 7(5):1429-37. PubMed ID: 11350914
    [Abstract] [Full Text] [Related]

  • 16. Furanylazaindoles: potent anticancer agents in vitro and in vivo.
    Lee HY, Pan SL, Su MC, Liu YM, Kuo CC, Chang YT, Wu JS, Nien CY, Mehndiratta S, Chang CY, Wu SY, Lai MJ, Chang JY, Liou JP.
    J Med Chem; 2013 Oct 24; 56(20):8008-18. PubMed ID: 24106982
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
    Beckers T, Reissmann T, Schmidt M, Burger AM, Fiebig HH, Vanhoefer U, Pongratz H, Hufsky H, Hockemeyer J, Frieser M, Mahboobi S.
    Cancer Res; 2002 Jun 01; 62(11):3113-9. PubMed ID: 12036922
    [Abstract] [Full Text] [Related]

  • 19. Anti-leukemia effects of the novel synthetic 1-benzylindole derivative 21-900 in vitro and in vivo.
    HuangFu WC, Chao MW, Cheng CC, Wei YC, Wu YW, Liou JP, Hsiao G, Lee YC, Yang CR.
    Sci Rep; 2017 Feb 09; 7():42291. PubMed ID: 28181578
    [Abstract] [Full Text] [Related]

  • 20. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo.
    Perchellet EM, Ladesich JB, Magill MJ, Chen Y, Hua DH, Perchellet JP.
    Anticancer Drugs; 1999 Jun 09; 10(5):489-504. PubMed ID: 10477169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.